Adagene, Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Its proprietary pipeline is comprised of novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.
Location of Key Operations
PricewaterhouseCoopers Zhong Tian LLP
IPO (February 9, 2021)
Raymond Tam, Internal
March 29, 2021: Adagene Announces Clinical Advancement for ADG116
February 9, 2021: Adagene Inc. Announces Pricing of Initial Public Offering